<DOC>
	<DOC>NCT00729183</DOC>
	<brief_summary>This study will evaluate the safety and treatment effect of 50 mg MK0822 with Vitamin D vs placebo with Vitamin D in postmenopausal women with low bone density.</brief_summary>
	<brief_title>BMD Efficacy and Safety of Odanacatib in Postmenopausal Women (0822-031)</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<criteria>Postmenopausal for 3 years, tscore &lt;=1.5 but &gt;3.5, hips contain no hardware from orthopedic procedures, ambulatory Patient has had a previous hip fracture Patient has had &gt;1 prior clinical vertebral fracture AND is a candidate for osteoporosis therapy Patient has been treated with oral bisphosphonates, strontium, PTH or other agents with an effect on bone Patient has had metabolic bone disorder other than osteoporosis Patient has renal stones, Parkinson's disease, MS or active parathyroid disease.</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>